Glucagon like peptide-1 and atherosclerosis

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 10, Issue 4, 2012, Pages 309-318

  Mita, Tomoya ^a   Watada, Hirotaka ^a  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherosclerosis; Diabetes; Endothelial cells; Glucagon like peptide 1; Macrophage monocyte; Smooth muscle cells

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALOGLIPTIN; ALPHA GLUCOSIDASE; APOLIPOPROTEIN B; CHOLESTEROL; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; LIRAGLUTIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; NATEGLINIDE; PLATELET DERIVED GROWTH FACTOR; SITAGLIPTIN; TRIACYLGLYCEROL;

ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ATHEROSCLEROSIS; DISEASE COURSE; DYSLIPIDEMIA; ENDOTHELIUM; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; MACROPHAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION;

EID: 84870275594     PISSN: 18715257     EISSN: 18756182     Source Type: Journal    
DOI: 10.2174/187152512803530388     Document Type: Article

References (96)

1. Greig, N.H.; Holloway, H.W.; De Ore, K.A.; Jani, D.; Wang, Y.; Zhou, J.; Garant, M.J.; Egan, J.M. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia, 1999, 42(1), 45-50.
2. Kolterman, O.G.; Buse, J.B.; Fineman, M.S.; Gaines, E.; Heintz, S.; Bicsak, T.A.; Taylor, K.; Kim, D.; Aisporna, M.; Wang, Y.; Baron, A.D. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab., 2003, 88(7), 3082-3089.
3. Parkes, D.G.; Pittner, R.; Jodka, C.; Smith, P.; Young, A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism: clinical and experimental 2001, 50(5), 583-589.
4. Kim, W.; Egan, J.M. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol. Rev., 2008, 60(4), 470-512.
5. Dupre, J.; Behme, M.T.; McDonald, T.J. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J. Clin. Endocrinol. Metab., 2004, 89(7), 3469-3473.
6. Szayna, M.; Doyle, M.E.; Betkey, J.A.; Holloway, H.W.; Spencer, R.G.; Greig, N.H.; Egan, J.M. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology. 2000, 141(6), 1936-1941.
7. Ross, R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med., 1999, 340(2), 115-26.
8. Cybulsky, M.I.; Iiyama, K.; Li, H.; Zhu, S.; Chen, M.; Iiyama, M.; Davis, V.; Gutierrez-Ramos, J.C.; Connelly, P.W.; Milstone, D.S. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J. Clin. Invest., 2001, 107(10), 1255-1262.
9. Despres, J.P.; Lamarche, B.; Mauriege, P.; Cantin, B.; Dagenais, G.R.; Moorjani, S.; Lupien, P.J. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N. Engl. J. Med., 1996, 334(15), 952-957.
10. Nigro, J.; Osman, N.; Dart, A.M.; Little, P.J. Insulin resistance and atherosclerosis. Endocr. Rev., 2006, 27(3), 242-259.
11. Rask-Madsen, C.; Li, Q.; Freund, B.; Feather, D.; Abramov, R.; Wu, I.H.; Chen, K.; Yamamoto-Hiraoka, J.; Goldenbogen, J.; Sotiropoulos, K.B.; Clermont, A.; Geraldes, P.; Dall'Osso, C.; Wagers, A. J.; Huang, P.L.; Rekhter, M.; Scalia, R.; Kahn, C. R.; King, G.L. Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. Cell Metab., 2010, 11(5), 379-389.
12. Engberding, N.; San Martin, A.; Martin-Garrido, A.; Koga, M.; Pounkova, L.; Lyons, E.; Lassegue, B.; Griendling, K.K. Insulinlike growth factor-1 receptor expression masks the antiinflammatory and glucose uptake capacity of insulin in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol., 2009, 29(3), 408-415.
13. Tabas, I.; Tall, A.; Accili, D. The impact of macrophage insulin resistance on advanced atherosclerotic plaque progression. Circ. Res., 2010, 106(1), 58-67.
14. Vicent, D.; Ilany, J.; Kondo, T.; Naruse, K.; Fisher, S.J.; Kisanuki, Y.Y.; Bursell, S.; Yanagisawa, M.; King, G.L.; Kahn, C.R. The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance. J. Clin. Invest., 2003, 111(9), 1373-1380.
15. Duncan, E.R.; Crossey, P.A.; Walker, S.; Anilkumar, N.; Poston, L.; Douglas, G.; Ezzat, V.A.; Wheatcroft, S.B.; Shah, A.M.; Kearney, M.T. Effect of endothelium-specific insulin resistance on endothelial function in vivo. Diabetes 2008, 57(12), 3307-3314.
16. Kubota, T.; Kubota, N.; Moroi, M.; Terauchi, Y.; Kobayashi, T.; Kamata, K.; Suzuki, R.; Tobe, K.; Namiki, A.; Aizawa, S.; Nagai, R.; Kadowaki, T.; Yamaguchi, T. Lack of insulin receptor substrate-2 causes progressive neointima formation in response to vessel injury. Circulation, 2003, 107(24), 3073-3080.
17. Han, S.; Liang, C.P.; DeVries-Seimon, T.; Ranalletta, M.; Welch, C.L.; Collins-Fletcher, K.; Accili, D.; Tabas, I.; Tall, A.R. Macrophage insulin receptor deficiency increases ER stressinduced apoptosis and necrotic core formation in advanced atherosclerotic lesions. Cell Metab., 2006, 3(4), 257-266.
18. Schneider, J.G.; Finck, B.N.; Ren, J.; Standley, K.N.; Takagi, M.; Maclean, K.H.; Bernal-Mizrachi, C.; Muslin, A.J.; Kastan, M.B.; Semenkovich, C.F. ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. Cell Metab., 2006, 4(5), 377-389.
19. Mita, T.; Goto, H.; Azuma, K.; Jin, W.L.; Nomiyama, T.; Fujitani, Y.; Hirose, T.; Kawamori, R.; Watada, H. Impact of insulin resistance on enhanced monocyte adhesion to endothelial cells and atherosclerogenesis independent of LDL cholesterol level. Biochem. Biophys. Res. Commun., 2010, 395(4), 477-483.
20. Mita, T.; Azuma, K.; Goto, H.; Jin, W.L.; Arakawa, M.; Nomiyama, T.; Suzuki, R.; Kubota, N.; Tobe, K.; Kadowaki, T.; Fujitani, Y.; Hirose, T.; Kawamori, R.; Watada, H. IRS-2 deficiency in macrophages promotes their accumulation in the vascular wall. Biochem. Biophys. Res. Commun., 2011, 415(4), 545-550.
21. Baumgartl, J.; Baudler, S.; Scherner, M.; Babaev, V.; Makowski, L.; Suttles, J.; McDuffie, M.; Tobe, K.; Kadowaki, T.; Fazio, S.; Kahn, C.R.; Hotamisligil, G.S.; Krone, W.; Linton, M.; Bruning, J.C. Myeloid lineage cell-restricted insulin resistance protects apolipoproteinE-deficient mice against atherosclerosis. Cell Metab., 2006, 3(4), 247-256.
22. Pratley, R.E.; Nauck, M.; Bailey, T.; Montanya, E.; Cuddihy, R.; Filetti, S.; Thomsen, A.B.; Sondergaard, R.E.; Davies, M. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet, 2010, 375(9724), 1447-1456.
23. Kirpichnikov, D.; Sowers, J.R. Diabetes mellitus and diabetesassociated vascular disease. Trends Endocrinol. Metab., 2001, 12(5), 225-230.
24. Otsuka, A.; Azuma, K.; Iesaki, T.; Sato, F.; Hirose, T.; Shimizu, T.; Tanaka, Y.; Daida, H.; Kawamori, R.; Watada, H. Temporary hyperglycaemia provokes monocyte adhesion to endothelial cells in rat thoracic aorta. Diabetologia, 2005, 48(12), 2667-2674.
25. Azcutia, V.; Abu-Taha, M.; Romacho, T.; Vazquez-Bella, M.; Matesanz, N.; Luscinskas, F.W.; Rodriguez-Manas, L.; Sanz, M.J.; Sanchez-Ferrer, C.F.; Peiro, C. Inflammation determines the proadhesive properties of high extracellular d-glucose in human endothelial cells in vitro and rat microvessels in vivo. PloS One, 2010, 5(4), e10091.
26. Balkau, B.; Shipley, M.; Jarrett, R.J.; Pyorala, K.; Pyorala, M.; Forhan, A.; Eschwege, E., High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care, 1998, 21(3), 360-367.
27. Fuller, J.H.; Shipley, M.J.; Rose, G.; Jarrett, R.J.; Keen, H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. Br. Med. J. (Clin. Res. Ed.)., 1983, 287(6396), 867-870.
28. Stratton, I.M.; Adler, A.I.; Neil, H.A.; Matthews, D.R.; Manley, S.E.; Cull, C.A.; Hadden, D.; Turner, R.C.; Holman, R.R. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 2000, 321(7258), 405-412.
29. Patel, A.; MacMahon, S.; Chalmers, J.; Neal, B.; Billot, L.; Woodward, M.; Marre, M.; Cooper, M.; Glasziou, P.; Grobbee, D.; Hamet, P.; Harrap, S.; Heller, S.; Liu, L.; Mancia, G.; Mogensen, C.E.; Pan, C.; Poulter, N.; Rodgers, A.; Williams, B.; Bompoint, S.; de Galan, B.E.; Joshi, R.; Travert, F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med., 2008, 358(24), 2560-2572.
30. Duckworth, W.; Abraira, C.; Moritz, T.; Reda, D.; Emanuele, N.; Reaven, P.D.; Zieve, F.J.; Marks, J.; Davis, S.N.; Hayward, R.; Warren, S.R.; Goldman, S.; McCarren, M.; Vitek, M.E.; Henderson, W.G.; Huang, G.D. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med., 2009, 360(2), 129-139.
31. Gerstein, H.C.; Miller, M.E.; Byington, R.P.; Goff, D.C., Jr.; Bigger, J.T.; Buse, J.B.; Cushman, W.C.; Genuth, S.; Ismail-Beigi, F.; Grimm, R.H., Jr.; Probstfield, J.L.; Simons-Morton, D.G.; Friedewald, W.T. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 2008, 358(24), 2545-2559.
32. Bonds, D.E.; Miller, M.E.; Bergenstal, R.M.; Buse, J.B.; Byington, R.P.; Cutler, J.A.; Dudl, R.J.; Ismail-Beigi, F.; Kimel, A.R.; Hoogwerf, B.; Horowitz, K.R.; Savage, P.J.; Seaquist, E.R.; Simmons, D.L.; Sivitz, W.I.; Speril-Hillen, J.M.; Sweeney, M.E. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ, 2010, 340, b4909.
33. Seaquist, E.R.; Miller, M.E.; Bonds, D.E.; Feinglos, M.; Goff, D.C., Jr.; Peterson, K.; Senior, P. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care, 2012, 35(2), 409-414.
34. Zoungas, S.; Patel, A.; Chalmers, J.; de Galan, B.E.; Li, Q.; Billot, L.; Woodward, M.; Ninomiya, T.; Neal, B.; MacMahon, S.; Grobbee, D.E.; Kengne, A.P.; Marre, M.; Heller, S. Severe hypoglycemia and risks of vascular events and death. N. Engl. J. Med., 2010, 363(15), 1410-1418.
35. Jin, W.L.; Azuma, K.; Mita, T.; Goto, H.; Kanazawa, A.; Shimizu, T.; Ikeda, F.; Fujitani, Y.; Hirose, T.; Kawamori, R.; Watada, H. Repetitive hypoglycaemia increases serum adrenaline and induces monocyte adhesion to the endothelium in rat thoracic aorta. Diabetologia, 2011, 54(7), 1921-1929.
36. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet, 1999, 354(9179), 617-621.
37. Nakagami, T. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia, 2004, 47(3), 385-394
38. Monnier, L.; Mas, E.; Ginet, C.; Michel, F.; Villon, L.; Cristol, J.P.; Colette, C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA, 2006, 295(14), 1681-1687.
39. Azuma, K.; Kawamori, R.; Toyofuku, Y.; Kitahara, Y.; Sato, F.; Shimizu, T.; Miura, K.; Mine, T.; Tanaka, Y.; Mitsumata, M.; Watada, H. Repetitive fluctuations in blood glucose enhance monocyte adhesion to the endothelium of rat thoracic aorta. Arterioscler. Thromb. Vasc. Biol., 2006, 26(10), 2275-2280.
40. Azuma, K.; Toyofuku, Y.; Iesaki, T.; Otsuka, A.; Tanaka, A.; Mita, T.; Hirose, T.; Tanaka, Y.; Daida, H.; Kawamori, R.; Watada, H. Acarbose, an alpha-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation. Biochem. Biophys. Res. Commun., 2006, 345(2), 688-693.
41. Tanaka, A.; Azuma, K.; Toyofuku, Y.; Kurokawa, A.; Otsuka, A.; Mita, T.; Hirosea, T.; Fujitani, Y.; Miyauchi, K.; Daida, H.; Kawamori, R.; Watada, H. Insulin and nateglinide reduce monocyte adhesion to endothelial cells in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation. Biochem. Biophys. Res. Commun., 2006, 350(1), 195-201.
42. Mita, T.; Otsuka, A.; Azuma, K.; Uchida, T.; Ogihara, T.; Fujitani, Y.; Hirose, T.; Mitsumata, M.; Kawamori, R.; Watada, H. Swings in blood glucose levels accelerate atherogenesis in apolipoprotein E-deficient mice. Biochem. Biophys. Res. Commun., 2007, 358(3), 679-685.
43. Barragan, J.M.; Rodriguez, R.E.; Blazquez, E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am. J. Physiol., 1994, 266(3 Pt. 1), E459-466.
44. Yamamoto, H.; Lee, C.E.; Marcus, J.N.; Williams, T.D.; Overton, J.M.; Lopez, M.E.; Hollenberg, A.N.; Baggio, L.; Saper, C.B.; Drucker, D.J.; Elmquist, J.K. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J. Clin. Invest., 2002, 110(1), 43-52.
45. Halbirk, M.; Norrelund, H.; Moller, N.; Holst, J.J.; Schmitz, O.; Nielsen, R.; Nielsen-Kudsk, J.E.; Nielsen, S.S.; Nielsen, T.T.; Eiskjaer, H.; Botker, H.E.; Wiggers, H. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am. J. Physiol. Heart Circ. Physiol., 2010, 298(3), H1096-1102.
46. Yu, M.; Moreno, C.; Hoagland, K.M.; Dahly, A.; Ditter, K.; Mistry, M.; Roman, R.J. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J. Hypertens., 2003, 21(6), 1125-1135.
47. Hirata, K.; Kume, S.; Araki, S.; Sakaguchi, M.; Chin-Kanasaki, M.; Isshiki, K.; Sugimoto, T.; Nishiyama, A.; Koya, D.; Haneda, M.; Kashiwagi, A.; Uzu, T. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun 2009, 380(1), 44-49.
48. Moreno, C.; Mistry, M.; Roman, R.J. Renal effects of glucagonlike peptide in rats. Eur. J. Pharmacol., 2002, 434(3), 163-167.
49. Gutzwiller, J.P.; Hruz, P.; Huber, A.R.; Hamel, C.; Zehnder, C.; Drewe, J.; Gutmann, H.; Stanga, Z.; Vogel, D.; Beglinger, C. Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion, 2006, 73(2-3), 142-150.
50. Moretto, T.J.; Milton, D.R.; Ridge, T.D.; Macconell, L.A.; Okerson, T.; Wolka, A.M.; Brodows, R.G. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebocontrolled, parallel-group study. Clin. Ther., 2008, 30(8), 1448-1460.
51. Gill, A.; Hoogwerf, B.J.; Burger, J.; Bruce, S.; Macconell, L.; Yan, P.; Braun, D.; Giaconia, J.; Malone, J. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc. Diabetol., 2010, 9, 6.
52. Blonde, L.; Klein, E.J.; Han, J.; Zhang, B.; Mac, S.M.; Poon, T.H.; Taylor, K.L.; Trautmann, M.E.; Kim, D.D.; Kendall, D.M. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes. Metab., 2006, 8(4), 436-447.
53. Klonoff, D.C.; Buse, J.B.; Nielsen, L.L.; Guan, X.; Bowlus, C.L.; Holcombe, J.H.; Wintle, M.E.; Maggs, D.G. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr. Med. Res. Opin., 2008, 24(1), 275-286.
54. Meier, J.J.; Gethmann, A.; Gotze, O.; Gallwitz, B.; Holst, J.J.; Schmidt, W.E.; Nauck, M.A. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia, 2006, 49(3), 452-458.
55. Schwartz, E.A.; Koska, J.; Mullin, M.P.; Syoufi, I.; Schwenke, D.C.; Reaven, P.D. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis, 2010, 212(1), 217-222.
56. Hsieh, J.; Longuet, C.; Baker, C.L.; Qin, B.; Federico, L.M.; Drucker, D.J.; Adeli, K. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia. 2010, 53(3), 552-561.
57. Ben-Shlomo, S.; Zvibel, I.; Shnell, M.; Shlomai, A.; Chepurko, E.; Halpern, Z.; Barzilai, N.; Oren, R.; Fishman, S. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMPactivated protein kinase. J. Hepatol., 2011, 54(6), 1214-1223.
58. Ban, K.; Noyan-Ashraf, M.H.; Hoefer, J.; Bolz, S.S.; Drucker, D.J.; Husain, M. Cardioprotective and vasodilatory actions of glucagonlike peptide 1 receptor are mediated through both glucagonlike peptide 1 receptor-dependent and -independent pathways. Circulation, 2008, 117(18), 2340-2350.
59. Richter, G.; Feddersen, O.; Wagner, U.; Barth, P.; Goke, R.; Goke, B. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am. J. Physiol., 1993, 265(4 Pt. 1), L374-381.
60. Hattori, Y.; Jojima, T.; Tomizawa, A.; Satoh, H.; Hattori, S.; Kasai, K.; Hayashi, T. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts antiinflammatory action in endothelial cells. Diabetologia, 2010, 53(10), 2256-2263.
61. Esposito, K.; Nappo, F.; Marfella, R.; Giugliano, G.; Giugliano, F.; Ciotola, M.; Quagliaro, L.; Ceriello, A.; Giugliano, D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation, 2002, 106(16), 2067-2072.
62. Liu, H.; Hu, Y.; Simpson, R.W.; Dear, A.E. Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasminogen [corrected] activator inhibitor-1 expression. J. Endocrinol., 2008, 196(1), 57-65.
63. Liu, H.; Dear, A.E.; Knudsen, L.B.; Simpson, R.W. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J. Endocrinol., 2009, 201(1), 59-66.
64. Gaspari, T.; Liu, H.; Welungoda, I.; Hu, Y.; Widdop, R.E.; Knudsen, L.B.; Simpson, R. W.; Dear, A.E. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/-mouse model. Diab. Vasc. Dis. Res., 2011, 8(2), 117-124.
65. Ceriello, A.; Esposito, K.; Testa, R.; Bonfigli, A.R.; Marra, M.; Giugliano, D. The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an endothelial resistance to glucagon-like peptide 1 in diabetes. Diabetes Care, 2011, 34(3), 697-702.
66. Yamagishi, S.; Imaizumi, T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr. Pharm. Des., 2005, 11(18), 2279-2299.
67. Ishibashi, Y.; Matsui, T.; Takeuchi, M.; Yamagishi, S. Glucagonlike peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem. Biophys. Res. Commun., 2010, 391(3), 1405-1408.
68. Shanmugam, N.; Reddy, M.A.; Guha, M.; Natarajan, R. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes, 2003, 52(5), 1256-1264.
69. Arakawa, M.; Mita, T.; Azuma, K.; Ebato, C.; Goto, H.; Nomiyama, T.; Fujitani, Y.; Hirose, T.; Kawamori, R.; Watada, H. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes, 2010, 59(4), 1030-1037.
70. Baggio, L.L.; Drucker, D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology, 2007, 132(6), 2131-2157.
71. Branen, L.; Hovgaard, L.; Nitulescu, M.; Bengtsson, E.; Nilsson, J.; Jovinge, S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler. Thromb. Vasc. Biol., 2004, 24(11), 2137-2142.
72. Gu, L.; Okada, Y.; Clinton, S. K.; Gerard, C.; Sukhova, G.K.; Libby, P.; Rollins, B.J. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell, 1998, 2(2), 275-281.
73. Aiello, R.J.; Bourassa, P.A.; Lindsey, S.; Weng, W.; Natoli, E.; Rollins, B.J.; Milos, P.M. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol., 1999, 19(6), 1518-1525.
74. Izeboud, C.A.; Monshouwer, M.; van Miert, A.S.; Witkamp, R.F. The beta-adrenoceptor agonist clenbuterol is a potent inhibitor of the LPS-induced production of TNF-alpha and IL-6 in vitro and in vivo. Inflamm. Res., 1999, 48(9), 497-502.
75. Chong, Y.H.; Shin, S.A.; Lee, H.J.; Kang, J.H.; Suh, Y.H. Molecular mechanisms underlying cyclic AMP inhibition of macrophage dependent TNF-alpha production and neurotoxicity in response to amyloidogenic C-terminal fragment of Alzheimer's amyloid precursor protein. J. Neuroimmunol., 2002, 133(1-2), 160-174.
76. Shames, B.D.; McIntyre, R.C., Jr.; Bensard, D.D.; Pulido, E.J.; Selzman, C.H.; Reznikov, L.L.; Harken, A.H.; Meng, X. Suppression of tumor necrosis factor alpha production by cAMP in human monocytes: dissociation with mRNA level and independent of interleukin-10. J. Surg. Res., 2001, 99(2), 187-193.
77. Aronoff, D.M.; Canetti, C.; Serezani, C.H.; Luo, M.; Peters-Golden, M., Cutting edge: macrophage inhibition by cyclic AMP (cAMP): differential roles of protein kinase A and exchange protein directly activated by cAMP-1. J. Immunol., 2005, 174(2), 595-599.
78. Mogi, C.; Tobo, M.; Tomura, H.; Murata, N.; He, X. D.; Sato, K.; Kimura, T.; Ishizuka, T.; Sasaki, T.; Sato, T.; Kihara, Y.; Ishii, S.; Harada, A.; Okajima, F. Involvement of proton-sensing TDAG8 in extracellular acidification-induced inhibition of proinflammatory cytokine production in peritoneal macrophages. J. Immunol., 2009, 182(5), 3243-3251.
79. Matsubara, J.; Sugiyama, S.; Sugamura, K.; Nakamura, T.; Fujiwara, Y.; Akiyama, E.; Kurokawa, H.; Nozaki, T.; Ohba, K.; Konishi, M.; Maeda, H.; Izumiya, Y.; Kaikita, K.; Sumida, H.; Jinnouchi, H.; Matsui, K.; Kim-Mitsuyama, S.; Takeya, M.; Ogawa, H. A dipeptidyl peptidase-4 inhibitor, des-fluorositagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein e-deficient mice. J. Am. Coll. Cardiol., 2012, 59(3), 265-276.
80. Kodera, R.; Shikata, K.; Kataoka, H.U.; Takatsuka, T.; Miyamoto, S.; Sasaki, M.; Kajitani, N.; Nishishita, S.; Sarai, K.; Hirota, D.; Sato, C.; Ogawa, D.; Makino, H. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia, 2011, 54(4), 965-978.
81. Sano, H.; Terasaki, J.; Mishiba, Y.; Imagawa, A.; Hanafusa, T. Exendin-4, a glucagon-like peptide-1 receptor agonist, suppresses pancreatic beta-cell destruction induced by encephalomyocarditis virus. Biochem. Biophys. Res. Commun., 2011, 404(3), 756-761.
82. Cipolletta, C.; Ryan, K.E.; Hanna, E.V.; Trimble, E.R. Activation of peripheral blood CD14+ monocytes occurs in diabetes. Diabetes. 2005, 54(9), 2779-2786.
83. Fukuhara-Takaki, K.; Sakai, M.; Sakamoto, Y.; Takeya, M.; Horiuchi, S. Expression of class A scavenger receptor is enhanced by high glucose in vitro and under diabetic conditions in vivo: one mechanism for an increased rate of atherosclerosis in diabetes. J. Biological. Chem., 2005, 280(5), 3355-3364.
84. Liang, C.P.; Han, S.; Okamoto, H.; Carnemolla, R.; Tabas, I.; Accili, D.; Tall, A.R. Increased CD36 protein as a response to defective insulin signaling in macrophages. J. Clin. Invest., 2004, 113(5), 764-773.
85. Mauldin, J.P.; Srinivasan, S.; Mulya, A.; Gebre, A.; Parks, J.S.; Daugherty, A.; Hedrick, C.C. Reduction in ABCG1 in Type 2 diabetic mice increases macrophage foam cell formation. J. Biol. Chem., 2006, 281(30), 21216-21224.
86. Nagashima, M.; Watanabe, T.; Terasaki, M.; Tomoyasu, M.; Nohtomi, K.; Kim-Kaneyama, J.; Miyazaki, A.; Hirano, T. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia, 2011, 54(10), 2649-2659.
87. Shah, Z.; Kampfrath, T.; Deiuliis, J.A.; Zhong, J.; Pineda, C.; Ying, Z.; Xu, X.; Lu, B.; Moffatt-Bruce, S.; Durairaj, R.; Sun, Q.; Mihai, G.; Maiseyeu, A.; Rajagopalan, S. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation, 2011, 124(21), 2338-2349.
88. Ta, N. N.; Li, Y.; Schuyler, C. A.; Lopes-Virella, M. F.; Huang, Y. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis, 2010, 213(2), 429-435.
89. Shah, Z.; Pineda, C.; Kampfrath, T.; Maiseyeu, A.; Ying, Z.; Racoma, I.; Deiuliis, J.; Xu, X.; Sun, Q.; Moffatt-Bruce, S.; Villamena, F.; Rajagopalan, S. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vascul. Pharmacol., 2011, 55(1-3), 2-9.
90. Doran, A.C.; Meller, N.; McNamara, C.A. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2008, 28(5), 812-819.
91. Ross, R. Cell biology of atherosclerosis. Annu. Rev. Physiol., 1995, 57, 791-804.
92. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J. Am. Coll. Cardiol., 2000, 35(5), 1122-1129.
93. Inaba, T.; Ishibashi, S.; Gotoda, T.; Kawamura, M.; Morino, N.; Nojima, Y.; Kawakami, M.; Yazaki, Y.; Yamada, N. Enhanced expression of platelet-derived growth factor-beta receptor by high glucose. Involvement of platelet-derived growth factor in diabetic angiopathy. Diabetes, 1996, 45(4), 507-512.
94. Li, S.L.; Reddy, M.A.; Cai, Q.; Meng, L.; Yuan, H.; Lanting, L.; Natarajan, R. Enhanced proatherogenic responses in macrophages and vascular smooth muscle cells derived from diabetic db/db mice. Diabetes, 2006, 55(9), 2611-2619.
95. Goto, H.; Nomiyama, T.; Mita, T.; Yasunari, E.; Azuma, K.; Komiya, K.; Arakawa, M.; Jin, W.L.; Kanazawa, A.; Kawamori, R.; Fujitani, Y.; Hirose, T.; Watada, H. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem. Biophys. Res. Commun., 2011, 405(1), 79-84.
96. Best, J.H.; Hoogwerf, B.J.; Herman, W.H.; Pelletier, E.M.; Smith, D.B.; Wenten, M.; Hussein, M.A. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care, 2011, 34(1), 90-95